Category Archives: Wisconsin Stem Cells

In their March 2006 report, the Institute of Medicine (IOM) showed overwhelming evidence of the existence of health related disparities for racial and ethnic minorities. The reports definition of cancer health related disparities refers to the unequal treatment of patient population groups the difference in treatment or access not justified by the differences in health status or preferences of the groups on the basis of race, ethnicity, and sometimes on the basis of gender, socioeconomic status, age or other patient characteristics.[1]

Over the last decade multiple medical societies and governmental agencies have studied the cause of cancer health disparities as well as attempted to identify solutions to the problem.

Five different studies being presented during the 61st annual meeting of the American Society of Hematology (ASH), held December 7 10, 2019 in Orlando, Florida, paint a mixed portrait of how demographics and socioeconomic status affect access to clinical trials and effective treatments for patients with blood cancers.

Some studies show encouraging evidence that racial minorities and older patients receive similar benefits compared to cancer treatments other patient groups receive. However, other studies show that their are still significant gaps in terms of care access and outcomes, underscoring the urgent need for renewed efforts to address disparities.

Inclusion is not only the right thing to do for our patients and our community its also the right thing to do if our goal is to create medicines that are truly targeted, noted Laura Michaelis, MD, Medical College of Wisconsin.

Clinical trialsBut the studies go beyond traditional healthcare. What is, for example, the impact of clinical trial inclusion criteria on cancer health disparities?

Based on data from a number of clinical trials, inclusion and exclusion criteria can become too restricting, limiting patient access. Other studies demonstrate that some of these criteria may result in the systematic exclusion minorities and older patients.

Our ability to achieve tailored treatments and prevention relies on including a wide and heterogeneous spectrum of individuals in clinical trials, Michaelis noted.

We have an obligation to recruit people who are traditionally absent from trials, including groups such as women, older people, minorities, people living in poverty, and people who are chronically ill or who have comorbidities, she concluded.

Socioeconomic Disparities in Survival of ChildrenA study by Lena E. Winestone, MD, MSHP and colleagues, at UCSF Benioff Childrens Hospital in San Francisco, shows that children from poorer neighborhoods were 2.4 times more likely to die during treatment for acute myeloid leukemia or AML than children from middle and high-income neighborhoods. [2]

The results of the study, funded by National Institutes of Health/National Cancer Institute (NIH/NCI), are based on an analysis of nearly 1,500 clinical trial participants. While previous research has pointed to racial disparities in cancer survival, the new study is the first to identify socioeconomic status as a key contributor to disparities among children with AML who were enrolled in clinical trials.

These findings are especially alarming because clinical trials are designed to provide consistent treatment across all participant groups. The fact that disparities were found despite the rigorous setting of clinical trials suggests that these disparities arise from a variety of factors outside of the specific chemotherapeutic therapy used.

We expected there to be a difference, but the degree of difference is quite substantial, Winestone, who is the lead study author, noted.

The more people are cognizant about the disparities that exist, the better positioned well be to ameliorate them, he added.

Researchers at UCSF Benioff Childrens Hospital and the Childrens Hospital of Philadelphia examined clinical trial data from children enrolled on two recent AML trials, AAML1031/NCT01371981 and AAML0531/NCT01407757, and used U.S. Census data to determine the median income and educational attainment in patients neighborhoods. [2]

They found that neighborhood socioeconomic factors were significant predictors of survival, even after accounting for insurance type, race, and known biologic risk factors.

While about 68% of patients from middle or high-income areas survived for five years following diagnosis, that proportion was 61% among patients from low-income areas and just 43% among patients living in poverty.

A significantly higher proportion of Black and Hispanic patients lived in poverty, low income, and low education areas. Researchers found that the racial disparity persisted even after accounting for neighborhood socioeconomic factors, suggesting Black patients face a significantly higher risk of death than white children living in areas of the same socioeconomic level.

The study did not determine the reasons behind the increased risk of death.

However, Winestone noted that one possibility is that toxic stress, which has been linked with lower socioeconomic status, may impact responses to chemotherapy or immune recovery following chemotherapy.

The researchers plan to further examine when patients died and the cause of death in the hopes of gaining insights as to whether the risks are connected to treatment-related causes or to the cancer itself.

Winestone also pointed out that in addition to drawing attention to persistent racial and socioeconomic disparities in cancer outcomes, the results also highlight potential additional data to be collected as part of clinical trials.

Rather than relying on neighborhood data as a proxy, she explained, it would be helpful if future clinical trials collected individual data on participants socioeconomic status at the time of enrollment.

If we could gather that information, it would allow us to dig deeper into the question of how someones circumstances outside of the clinical aspects of their disease impact their health outcomes, Winestone concluded.

Racial Disparities and comorbidities and/or organ dysfunctionA study of more than 1,000 patients with AML revealed that African Americans were more likely to have evidence of abnormal kidney functioning than whites, but this was not associated with any difference in overall survival. [3]

The findings have implications for the design of clinical trials, which typically exclude patients with signs of kidney dysfunction and may, as a result, disproportionately, and unnecessarily, exclude minorities from participating in clinical trials.

Its important that we understand how drugs work in different patient populations in clinical trials, especially those that reflect the patients we will eventually treat with the drug, said lead study author Abby Statler, Ph.D, of Cleveland Clinic.

Designers of clinical trials can use data from studies like ours to inform future eligibility criteria in order to test drugs in more diverse populations, Statler further noted.

Clinical trials test the effectiveness of new treatments and identify any safety concerns before a drug can be sold on the market. Trials often seek to enroll patients who have only a few health problems (called comorbidities)other than the one being studied. This approach makes it easier to tell if study outcomes are related to the use of the experimental drug rather than influenced by a patients other health conditions or medications. However, because patients in racial minorities may, on average, have more comorbidities, this practice may disproportionately exclude these individuals from clinical trials. As a result, the population of trial participants does not reflect the real-world diversity of the patient population who will ultimately receive the investigational drug following regulatory approval.

In this study, researchers examined health records from 1,040 AML patients receiving care at Cleveland Clinic from 2003-2019. They found no significant differences between African American and white patients in treatment approaches, rates of responsiveness to treatment, or overall survival, suggesting that treatments worked just as well in African Americans as whites.

However, the study demonstrated that African Americans were significantly more likely to have abnormal creatinine and creatinine clearance, signs that the kidneys are not clearing waste products from the bloodstream as effectively as they should. However, this abnormality may be benign, as previous studies suggest African Americans have higher creatinine levels than whites. Consequently, this laboratory value may falsely underestimate this subpopulations kidney function, causing them to fail study enrollment requirements that require normal creatinine or creatinine clearance values.

The researchers observed that patients with minor creatinine or creatinine clearance abnormalities showed no differences in overall survival. This, they noted, calls into question the necessity of excluding patients with these abnormalities from AML trials.

The study, Statler noted, also bolstered evidence that African Americans may simply have higher baseline creatinine levels than white patients.

These findings suggest trials might be able to broaden their criteria to include patients with kidney disease without compromising the safety of the participants, said Statler.

In doing so, we might be able to truly improve the number of patients from minority populations who are potentially eligible for trials but who would have been excluded for that reason alone, she said.

The study also examined markers for a variety of comorbidities including endocrine, gastrointestinal, liver, cardiovascular, and neurological functioning. Of these, liver dysfunction was the only comorbidity that was associated with diminished survival. The researchers plan to further examine the data to determine precise kidney function cutoff points for future clinical trial eligibility criteria.

Statler concluded that in addition to AML the study findings could be relevant to designing trials for other cancers, particularly prostate cancer, which disproportionately affects African American men.

A Hands-On ApproachA study of 182 patients treated for diffuse large B-cell lymphoma (DLBCL) at a safety net cancer center reports that non-white patients had similar health outcomes to white patients. The findings contrast previous population-based studies pointing to racial disparities in lymphoma outcomes and suggest possible steps tertiary centers can take to help close the gap. [4]

Researchers at the Levine Cancer Institute study found no significant differences between racial groups in terms of overall survival or survival without disease progression at two years. Racial groups also had similar rates of relapse, stem cell transplantation, and clinical trial enrollment. While the study does not indicate a specific reason for the lack of disparities, researchers suggest historically underserved patients may have benefited from hands-on assistance through the institutions patient navigator program, which was used by 85% of patients in the study.

The scientific literature shows that racial minorities tend to have poorer outcomes in lymphoma and several other diseases, and we wanted to know if that holds true at our institution, said senior study author Nilanjan Ghosh, MD, Ph.D, of Levine Cancer Institute.

We found that minorities do not have worse outcomes for DLBCL if the disease is optimally managed, which requires that all patients have access to care. It shows that if you work on addressing socioeconomic barriers, you can get equal results.

The centers patient navigator program is designed to help patients address logistical barriers to keeping appointments and staying on track with their cancer treatment.

For example, navigators can help patients who are homeless take advantage of lodging that is available for patients undergoing cancer treatment. They can also help arrange transportation for patients without a car. And navigators can help coordinate care across providers such as primary care physicians, oncologists, and other specialists.

Analyzed data related to patients treated for newly diagnosed DLBCL between 2016-2019, the researchers noted that about four out of five patients identified themselves as white. On average, 73% of non-white patients identifying themselves as African American and 15% identified as Hispanic.

White patients were significantly more likely to have private health insurance and less likely to have government insurance or no insurance than non-whites. In addition, white patients were slightly older than non-white patients.

Despite the differences in health insurance type, the researchers also found that white and non-white had similar rates of overall survival (74% and 81%, respectively) two years after diagnosis, as well as similar rates of progression-free survival (60% and 63%, respectively). Treatment regimens and outcomes for those with relapsed or refractory DLBCL were, according to the researchers, also similar among groups.

Age Should Not Be a BarrierEven though autologous hematopoietic cell transplantation (AHCT), a form of stem cell therapy, is an effective treatment for multiple myeloma, only four out of 10 patients receive this therapy. A new study by Anita DSouza, MD, Medical College of Wisconsin, and colleagues demonstrated that AHCT is safe and effective in older patients and suggests that more people could benefit from the therapy than have typically been offered it. [5]

Older people are often excluded from clinical trials studying transplant because they tend to have a greater number of health issues. Without trials proving newer, aggressive treatments are safe for older patients, doctors may avoid them on the assumption that they are too risky. In addition to showing AHCT is safe and effective in patients over 70 years of age. The researchers also found patients fared better when given the conditioning chemotherapy drug melphalan (Alkeran) in the normal dose of 200 mg/m2, rather than the reduced dose of 140 mg/m2 often given to older patients.

This study shows that you can perform these transplants safely in older patients, and the older patients get the same benefits from these treatments as the younger patients do, DSouza, who is the studys lead author, noted.

In addition, if there are no contraindications other than simply age, its worth trying the higher dose of melphalan. Age alone should not be a reason to automatically reduce the dose, DSouza added.

According to DSouza, the study strengthens the argument that people should not just be excluded from clinical trials based on age alone. Multiple myeloma is the second most common blood cancer, and it occurs most often in older adults. Half of patients are age 70 or older at the time of diagnosis.

Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, the researchers examined health records of approximately 16,000 patients who received AHCT with melphalan in the United States between 2013-2017.

After adjusting for factors such as functional status, comorbidities, and disease stage, they found patients who received their treatments at age 70 or older had similar rates of relapse or disease progression, progression-free survival, and death not caused by a cancer relapse as those 60-69 years of age.

Of patients age 70 and older, about 40% received the full dose of melphalan and 60% received a reduced dose. Those receiving the reduced dose had significantly worse outcomes and lower survival rates. However, DSouza noted that it is impossible to determine whether these patients were also more frail to begin with, in which case their poorer outcomes would not necessarily be due to the dosing reduction.

While AHCT specialists often support the use of AHCT in otherwise healthy older patients, DSouza noted that oncologists in community hospitals where many patients are first treated often fail to refer older patients to transplant centers. The researchers noted a significant increase in the proportion of older patients receiving AHCT in 2017 compared to 2013, suggesting that referrals to AHCT specialists increased over time.

In addition to age disparities, the study also speaks to important racial disparities in the care of patients with myeloma, a disease which is twice as common in African Americans as whites. Yet AHCT rates are significantly lower among black patients, which made DSouza concluded that age likely adds to the barriers for these patients.

CAR T-cell therapy Reduces Health Care Utilization in Older PatientsA new analysis of Medicare claims data offers the first real-world evidence using claims data available after the approval of autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy. [6]

These analyses, Karl M. Kilgore, Ph.D, of Avalere Health observed, shows that CAR T-cell therapy may be beneficial for a broad population of older patients with DLBCL, including those with multiple chronic conditions. The research also shows patients spent less time in the hospital and had lower health care costs after CAR T-cell therapy than they did in the months leading up to it.

The U.S. Food and Drug Administration (FDA) approved the first CAR T-cell therapy for adults with DLBCL in 2017. However, many of the patients included in the clinical trials leading up to that approval were middle-aged, with a median age of 56-58. This study used the earliest available Medicare claims data to assess the treatments use in Medicare patients age 60 and older, who comprise the majority of Medicare beneficiaries and often have multiple chronic health issues.

Our findings offer evidence that older patients with multiple comorbidities can be treated successfully with CAR T-cell therapy, Kilgore, who is the lead study author, said.

While we dont know the long-term outcomes yet, nearly three-quarters of the patients were still alive six months post-treatment. Even in that narrow window of time we saw a significant decline in health care utilization including hospitalizations and emergency room use, which is suggestive of a successful course of treatment, Kilgore concluded.

DLBCL, a cancer that starts in the white blood cells, accounts for about one-third of the 74,000 cases of non-Hodgkin lymphoma diagnosed in the United States each year. About 63% of patients survive for five years after their diagnosis. For those who relapse or have refractory disease, treatment options include chemotherapy, stem cell transplantation, and CAR T-cell therapy. CAR-T works by re-engineering a patients own T-cells, part of the immune system, to kill cancer cells. Multiple steps are required to collect, modify, and re-infuse T-cells into the patient, a process that is typically combined with lympho-depleting chemotherapy and a single infusion of the patients modified T-cells.

The researchers analyzed claims data from patients enrolled in Medicare Fee For Service parts A and B October 2017-September 2018. They identified 207 patients with an average age of 70 years who had undergone CAR T-cell therapy for DLBCL. Half underwent CAR T-cell therapy as part of a clinical trial, while the remainder had comorbidities that likely would have excluded them from CAR T-cell clinical trials.

Comparing health care utilization in the six months before and after CAR-T therapy, the researchers found patients average overall health care costs dropped by 39% after undergoing CAR-T, excluding the cost of the CAR-T treatment itself. In the months following CAR-T, patients spent less time in the hospital and had half as many emergency department visits than before the therapy.

Only 7.2% had any evidence of subsequent chemotherapy in the claims data, suggesting that the cancer had not returned within the first six months following CAR T-cell therapy for most patients.

Clinical trialsBortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01371981Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 NCT01407757

Reference[1] McGuire TG, Alegria M, Cook BL, Wells KB, Zaslavsky AM. Implementing the Institute of Medicine definition of disparities: an application to mental health care. Health Serv Res. 2006;41(5):19792005. doi:10.1111/j.1475-6773.2006.00583.x [Abstract][2] Winestone LE, Getz KD, Bona KO, Fisher BT, Gamis AS, Seif AE, Sung L, Wang YC, Alonzo TA, and Aplenc R. Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Childrens Oncology Group. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 906. Outcomes ResearchMalignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid DiseasesHematology Disease Topics & Pathways: Diseases, AML, Pediatric, Study Population, Clinically relevant, Myeloid Malignancies. [Abstract][3] Statler A, Hobbs BP, Radivoyevitch T, Mukherjee S, Bell K, Advani AS, Gerds AT, Nazha A, Patel BJ, Carraway HE, and Sekeres MA. Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction? 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 903. Health Services ResearchMalignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies | Hematology Disease Topics & Pathways: Diseases, AML, Adult, Study Population, Myeloid Malignancies [Abstract][4] Hu B, Chen T, Boselli D, Bose R, JSymanowski JT, Raghavan D, Soni A, Park SI, Avalos BR, Copelan EA, Jacobs R, Ghosh N. Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral. Session: 905. Outcomes ResearchMalignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies. Hematology Disease Topics & Pathways: Adult, Diseases, Non-Hodgkin Lymphoma, DLBCL, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement.[Abstract][5] Munshi PN, Hari P, Vesole DH, Jurczyszyn A, Zaucha J, Davila O, Kumar SK, Shah ND, Qazilbash MH, DSouza A. Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders | Hematology Disease Topics & Pathways: Adult, Study Population. [Abstract][6] Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum A, Shah GL. Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: OralSession: 905. Outcomes ResearchMalignant Conditions (Lymphoid Disease): CAR T and Novel Therapies Coming of Age: Real-World and Patient-Centered Outcomes. Hematology Disease Topics & Pathways: Diseases, Biological, Therapies, CAR-Ts, Non-Hodgkin Lymphoma, DLBCL, Lymphoid Malignancies. [Abstract]

See the original post:
Addressing Disparities in Cancer: Factors Influencing Care, Access and Outcomes - OncoZine

Paul Ausman and Raquel Hoepner-Ausman suffered traumatic brain injuries 16 days apart in April 2017. Two-and-a-half years later, both Paul and Raquel are on the comeback trail.

Paul Ausman was never shy about throwing a curveball during his days as a professional baseball pitcher.

But Ausman and his family have seen more curveballs in recent years than many families see in a lifetime.

After both Paul and his wife suffered significant brain ailments 16 days apart in April 2017, theyve continued battling and two-and-a-half years later they and their family are on the comeback trail.

While their road to recovery is far from over, they move into Thanksgiving improving every day with plenty to be thankful for.

Raquel and Paul's injuries came when their son Andrew (center) was a senior at McDonell. Andrew is now a junior at UW-Eau Claire.

Sixteen days

Raquel Hoepner-Ausman worked at Macys in Oakwood Mall for 26 years until the store closed in March 2017. A month later she collapsed after suffering a brain aneurysm in her familys home in Chippewa Falls and was taken to HSHS Sacred Heart Hospital in Eau Claire before being airlifted to Regions Hospital in St. Paul, Minnesota.

A little more than two weeks later, Paul was taken to the emergency room at HSHS St. Josephs Hospital in Chippewa Falls being before taken to Regions and diagnosed with having a brain tumor the size of a golf ball.

Both Paul and Raquel faced grueling recovery roads as their daughter Nikki lived in the Minneapolis with her family and a full-time job, and their younger son Andrew was finishing his senior year at McDonell.

A day after being admitted into Regions, Paul had a brain biopsy and was diagnosed with Lymphoma of the brain, and on May 4, 2017, had surgery for an enlarged lymph node.

Pauls vocal cord was accidentally nicked during the procedure and he lost his voice and could barely talk. The beginning of the same month, Raquel was transferred to a long-term care hospital in St. Paul and started to relearn to speak, eat and respond to commands.

She was later moved to a nursing home in Bloomer before needing brain surgery less than a year later to repair a blood vessel in her brain and had to start the process of relearning to eat, speak and respond to commands all over again.

Paul was approved for stem cell therapy and underwent his first attempt at a stem cell transplant on Sept. 28, 2017, in Rochester, Minn.

However, less than a month later, Paul was diagnosed with lymphoma cancer in both eyes, putting the stem cell transplant on hold while multiple surgeries were performed in both eyes to attempt to remove cancer cells. Follow-up chemotherapy injections into his eyes were performed until the start of the stem cell procedure, which he was able to restart in February 2018.

Paul was discharged from the stem cell transplant hospital on March 27, 2018, one day before Raquel had her brain surgery.

Raquel moved to the Rutledge home in Chippewa Falls in early June, across the street from the Ausman home, where she currently resides and rehabilitates.

Paul continued to receive chemotherapy shots in his eyes to keep the lymphoma in remission and recently has moved to a daily pill. Paul still makes monthly trips to Rochester as his body rebuilds its immune system.

B.A.T.

Paul graduated from Eau Claire Regis High School and was drafted in the 14th round of the 1973 Major League Baseball amateur draft by the Milwaukee Brewers. He played in the minor leagues for five seasons with the Brewers and Minnesota Twins, compiling a 2.93 earned run average across 147 games and 276 innings.

He reached as high as AAA with the Twins and nearly cracked the big league roster as the final cut during spring training.

The left hander shared the field with future Hall of Famers such as Robin Yount, Dave Winfield, Jack Morris, Rod Carew, Alan Trammel and Bert Blyleven before his career was finished after the 1977 season.

Paul would return to the area and earn his bachelor degree at the University of Wisconsin-Eau Claire before getting his masters from the University of Iowa.

He worked a number of jobs in the area, most recently as a store manager for the Mega Holiday station near the Family Fare grocery store downtown in Chippewa Falls.

When the Ausman family needed help, it came from a familiar face to the Chippewa Falls baseball community.

In the days and months after Paul and Raquel suffered their initial ailments, medical bills started piling up, as did the stress of figuring out how to take care of the bills. The family researched grants that could help them with their mounting medical costs, but nothing they found would shoulder the load.

Thats when Joe Vavra came into play.

The Chippewa Falls native and longtime MLB coach met Ausman after Vavra was drafted by the Los Angeles Dodgers in the eighth round of the 1982 draft.

We can't do it without you. Support local journalism with our BEST DEAL EVER!

Please call 877-782-0193 to upgrade your subscription.

Read the original here:
Ausman family thankful for recoveries, support from family and community - Chippewa Herald

ITS a terrifying thought but having nightmares could help us prepare for potentially frightening situations.

Theres a huge amount science still doesnt know about dreaming and its not even clear if everyone does it. We all experience rapid eye movement (REM) the stage of sleep when dreams occur.

But whether those who claim they never dream really dont, or do dream but simply dont remember it after waking, isnt clear.

Nor is the mechanism by which dreams are formed in the brain entirely understood, never mind why it happens.

However, many neuroscientists have long believed that bad dreams allow us to safely act out potentially dangerous situations before they occur in real life.

And the new findings from a study at the University of Geneva and University Hospitals Geneva, and the US University of Wisconsin, seem to add weight to that theory.

The researchers asked 18 volunteers to wear EEG headsets while they slept and then woke them multiple times during the night to ask them a series of questions about whether theyd been dreaming, and if that dream involved fear.

They then compared the volunteers answers with their mapped brain activity during sleep and discovered that during scary dreams, two areas of the subjects brains were particularly active: the insula and the cingulate cortex.

During the day, the insula is involved in identifying and evaluating emotional responses, while the cingulate cortex is responsible for preparing the bodys physical reaction to perceived threats the famous fight or flight response.

In the second part of the study, 89 participants kept a dream diary for a week, and were shown a series of distressing images while lying in an MRI scanner.

The images triggered less of a response in the two brain regions studied, and in the amygdala the brains fear centre in subjects who reported having a lot of frightening dreams than patients who reported few or none.

Patients who had more bad dreams showed more activity in the medial prefrontal cortex, a region of the brain thats known to dampen down the fear response.

Lead researcher Lampros Perogamvros said: Dreams may be considered as real training for our future reactions, and may potentially prepare us to face real-life dangers.

ITS about 40,000 years since the Neanderthal disappeared about the same time since modern humans started expanding out of Africa towards Europe and the Middle East.

Because those dates match up so well, its always been assumed the latter caused the former, but a study suggests the Neanderthals may have become extinct for reasons that were nothing to do with the arrival of homo sapiens.

A team at Eindhoven University of Technology in the Netherlands produced computer models to simulate the effects of various factors on Neanderthal populations of different sizes from 50 to 5,000 based on data gleaned from studies of modern hunter-gatherer populations worldwide.

Factors modelled included inbreeding, fluctuations in birth and death rates, changes in the ratio of the sexes and Allee effects a phenomenon first identified in the 1950s whereby, in a shrinking population, the average health and fitness of each individual tends to decline over time.

The researchers found that Allee effects alone could explain the extinction of any population numbering less than 1,000 individuals, while inbreeding plus Allee effects could easily account for the entire Neanderthal species decline over a 10,000-year period, without modern humans arrival having any effect at all.

The papers lead author Krist Vaesen said: Did Neanderthals disappear because of us? No, this study suggests. The species demise might have been due merely to a stroke of bad demographic luck.

The true picture, say the researchers, is probably a more complex amalgam of the two mechanisms. For instance, conflict with incoming humans may have caused an acceleration of Allee effects within the population, as well as simply reducing its size.

FLIGHT feathers are masterpieces of evolution: helping penguins swim, eagles soar and hummingbirds hover.

Now scientists have shed light on how feathers developed and helped birds spread across the world.

Weve always wondered how birds can fly in so many different ways and we found the difference in flight styles is largely due to the characteristics of their flight feathers, said Cheng-Ming Chuong, lead researcher of a global team led by the University of Southern California. Experts in stem cells, molecular biology, anatomy, physics and bio-imaging studied bird species of different styles including ostriches, sparrows, eagles, ducks, penguins and hummingbirds.

Feathers found in 100million-year-old amber had barbs, which could overlap each other but could not become a tight flat plane for flying. Feather shafts gradually became stronger yet more lightweight, leading to stiffer feathers and sturdier wings.

80 Per cent The proportion of school-going children aged 11 to 17 who get less than one hour of physical activity a day, according to the World Health Organization

4 BPM The average heart rate of a diving blue whale, as measured by researchers at Stanford University

HIBERNATING animals ability to pile on the pounds before the winter and wake up months later as fit as ever has led researchers to an intriguing link with obesity. After comparing the genomes of four animals a squirrel, a bat, a lemur and a Madagascan tenrec scientists at the University of Utah believe they have evolved ways to turn off areas that control genes linked to obesity.

A NEW technique that turns brewery waste into carbon, which can be used as barbecue charcoal, has been developed at Queens University Belfast. The UK currently imports liquid carbon from the Middle East and pellets from the US, but the new method may reduce the need to do so. If successful, it could lower carbon emissions by reusing 3.4million tons of waste grain produced by brewers each year, researchers say.

Many animals will choose where they stand to maximise camouflage. The common baron caterpillar has a stripe that looks like the central rib of the mango leaves it eats so natural selection has clearly favoured caterpillars that line themselves up with the rib. But it seems unlikely individual caterpillars know why they do this; its simply programmed into their genes. This is true of all invertebrates and most fish, reptiles and amphibians, but some more intelligent species do show some awareness. Japanese quail, for instance, lay eggs with patterns that vary widely from one bird to another. A 2013 study at Abertay University in Dundee found quail who laid darker eggs were more likely to select darker nesting sites, and vice versa.

The Adams apple is the notch at the top of the thyroid cartilage one of nine cartilages in the protective skeleton around the larynx (voice box). Men and women both have them, but they tend to be larger and more visible in men because their thyroid cartilage grows more during puberty, enlarging the larynx and deepening the voice. The Adams apple itself serves no particular purpose and can be reduced in size without changing the nature of the voice in gender reassignment surgery, for example.

Based on stories featured in BBC Science Focus magazine. Head to sciencefocus.com/metro for the latest science news and a special subscription offer for Metro readers

The ethics of Nazi research dissected

What really happens in near-death experiences

Having babies in space

Go here to read the rest:
Lab: Nightmares may help the brain prepare for frightening situations in real life - Metro Newspaper UK

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues and tumors, wherein their toxicity, impurity, and other aspects are studied.

With the growing number of successful stem cell therapy treatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Continued here:
Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton...

LIST OF SPEAKERS

.

Siew-Lan Ang,Crick Institute, UK

Ernest Arenas,Karolinska Institutet, Sweden

Rajeshwar Awatramani,Northwestern University, USA

Anders Bjorklund,University of Lund, Sweden

Sandra Blaess,University of Bonn Germany

Vania Broccoli,San Raffaele Scientific Institute/CNR Institute of Neuroscience, Italy

Claude Brodski,Ben Gurion University, Israel

Huaibin Cai,NIH National Institute on Aging, USA

Wolfgang Driever,University of Freiburg, Germany

Siew-Lan Ang,Crick Institute, UK

Su-Chun Zhang,University of Wisconsin-Madison/Duke-NUS Medical School, USA

Cecilia Flores,McGill University, Canada

Mary Hynes,Stanford University, USA

Jeff Kordower,Rush University, USA

Martin Lvesque,Laval University,CERVO Brain Research Centre, Canada

Emmanouil Metzakopian,UK Dementia Research Institute (UK DRI),University of Cambridge, UK

Lia Panman,MRC Toxicology Unit, Cambridge, UK

Janelle Drouin-Ouellet,University of Montreal, Canada

Juha Partanen,University of Helsinki, Finland

Jeroen Pasterkamp,University Medical Center Utrecht, The Netherlands

Thomas Perlmann,Karolinska Institutet, Sweden

Nilima Prakash,Hamm-Lippstadt University of Applied Sciences, Germany

Alain Prochiantz,College de France, France

Jens Schwammborn,University of Luxembourg, Luxembourg

Marten P. Smidt,University of Amsterdam, The Netherlands

Lorenz Studer,Memorial Sloan Kettering Cancer Center, USA

Louis-Eric Trudeau,University of Montreal, Canada

Andrea Wizenmann,Univeristy of Tbingen, Germany

Wolfgang Wurst,Helmholtz Zentrum mnchen, German Research Center for Environmental Health, Germany

Link:
Development of the dopaminergic system - from stem cells ...

Stem Cell Therapy for General Back Pain

At Wisconsin Stem Cell Therapy, we specialize in back pain treatment. We have pioneered the industrys latest proven alternatives to surgery and steroids. Our in-office, same-day procedures will alleviate your back pain regardless of the cause. We treat a range of conditions including spondylolisthesis, spinal arthritis, intervertebral disc degeneration, spinal stenosis and herniated discs. Even those with little or no cartilage around their discs have benefited from Wisconsin Stem Cell Therapys procedures.

Wisconsin Stem Cell Therapys revolutionary platelet rich plasma (PRP) and Stem Cell Therapy procedures treat all the damages and underlying conditions that cause you pain. Our doctors will inject these cells to the target area, and they then act as an immunologically privileged material to rebuild and strengthen the damaged tissue which causes back pain.

Osteoarthritis is the degeneration of the protective cartilage that covers the ends of the bones in the joints. It is also known as degenerative arthritis or wear and tear arthritis. The protein that makes up the cartilage degenerates by forming tiny cracks or by flaking. This can eventually result in a total loss of cartilage. Once the cartilage is lost, the friction between the bones can stimulate spurs or bony growths to form around the joints.

Rather than going for the traditional treatments, you can visit Wisconsin Stem Cell Therapy for a non-invasive alternative. Our same-day procedure eliminates the pain, recovery time and risk associated with traditional treatments. Our procedure also treats the underling damage that causes the pain. Wisconsin Stem Cell Therapy treatment for osteoarthritis typically includes a combination of Stem Cell Therapy and our advanced form of platelet rich plasma (PRP) therapy which has been fortified and enhanced with additional natural growth factors and cytokines.

Lumbar arthritis is chronic inflammation of the soft tissues within the joints of the lower back. Cartilage discs that sit between each vertebrae provide support and stability for the constant movement in the back. When the supportive tissues are damaged from injury or begin to deteriorate, painful swelling and inflammation can occur from friction between the bones.

Arthritis can become an ongoing, chronic issue that not only causes pain, stiffness, and swelling, but can limit mobility and the ability to perform daily activities. The use of regenerative medicine techniques can eliminate the inflammation that causes symptoms of lumbar arthritis. Stem Cell Therapy is a procedure that uses healing cells to target pain areas, reduce inflammation, and even generate new growth of supportive soft tissues.

Facet syndrome is a condition that affects the small joints between the vertebrae that make up the spine and is one of the most common conditions causing lower back and neck pain. These joints are constantly moving, providing the stability and flexibility needed to walk, sit, turn, and bend. Each of these small joints of the neck and spine contain soft tissues and cartilage that absorb shock during these movements and are important to protect the bones from rubbing against each other and causing friction. This can cause inflammation and swelling of the joints, headaches, and make even slight movements painful.

Facet syndrome has historically been difficult to treat, but new developments in regenerative medicine offer new, advanced treatment options. Stem Cell Therapy is a natural alternative to the risks of medications, steroid injections, and surgery. By using these regenerative cells, our specialists can target specific areas of pain and inflammation to alleviate pain and trigger an immune response that helps heal damaged tissues. Our non-invasive procedures can be done in a same-day, in-office visit.

The spine is made up of several vertebrae, separated by soft tissue and cartilage that provides cushioning between the bones. The cartilage between each bone is called a disc, and each disc keeps the bones from rubbing against one another. Disc degeneration occurs when this cartilage wears down or becomes damaged.

If left untreated, disc degeneration can limit mobility, and lead to bone spurs and chronic pain. People suffering from back problems no longer have to settle for pain medications, steroid injections, or risky surgical procedures. Stem Cell Therapy is an advanced, non-surgical procedure that rebuilds degenerating discs and tissues. Our team of specialists is experienced in finding the right treatment options that can reduce inflammation and the development of scar tissue, and get you feeling better fast.

See the article here:
Stem Cell Therapy for Back Conditions Oconomowoc, WI

Umbilical cord cells include stem cells, growth factors and a range of other beneficial proteins and compounds. We use blood from the umbilical cord which has been purified to get rid of any harmful substances that might cause rejection of the treatment by your body. We inject the treated cord blood into the affected area, where the various active compounds found in cord cells go to work immediately to begin inflammation reduction and the promotion of healthy cell division and renewal. Some of the active compounds at work include VEGF (Vascular Endothelial Growth Factor), IL-LRA (Interleukin-1, a receptor antagonist, stem cell factors (SCF), FGF-2 (Fibroblast Growth Factor-2) and Transforming Growth Factor-beta (TGF-beta). Each of these compounds has a slightly different effect, but the net result is that the damaged cells in your joints are given the ingredients they need to kick-start healthy renewal and regeneration. The injection changes the chemistry inside the joint, creating a healthier environment that encourages positive, healing changes to take place. A better blood supply to the area, a reduction in damaging chronic inflammation and stimulation of healthy tissue growth are all typical consequences of the minimally invasive stem cell treatments we provide. By using umbilical cord cells in this way, its possible to transform joint therapy into a holistic healing process that prompts the body to enhance its own regenerative efforts. This results in a natural process of joint health improvement in the weeks or months following the injection.

Link:
Wisconsin Stem Cell Clinic - Forward Healthy Lifestyles

Stem Cell Therapy for General Knee Pain

Knee pain can severely limit your ability to live an active, healthy life. Many people live for years with chronic knee pain that can make it difficult to work, exercise, and spend time with loved ones. Symptoms may include difficulty bending or stretching out the leg, difficulty putting weight on the knee, trouble walking and running, and feeling pain with other normal movements. The knee may lock up or give out. There are many causes for knee pain, including injury, overuse, regular wear and tear, and common joint conditions. When the knee is hurting, its important to rest and avoid causing more stress to the joint. If the knee pain or swelling doesnt go away or goes away temporarily and keeps coming back, then its time to seek professional treatment. Knee pain and swelling that is sudden and intense may require emergency treatment. Knee pain may gradually get worse and then suddenly become a serious problem.

Traditionally, chronic knee pain is treated with cortisone injections that offer only temporary results, overused pain medications that simply mask the symptoms, and risky knee surgeries that may not always be effective and require lengthy recovery times. At Wisconsin Stem Cell Therapy, we treat knee pain with stem cell therapies that heal the knee conditions naturally using the bodys own regenerative abilities without medications or surgery. These stem cell treatments work to repair damaged tissues, ligaments, muscles, tendons, cartilage, and bone fractures. These procedures treat the underlying cause of the joint pain and have little to no risk of the unwanted side effects seen in traditional treatments.

Osteoarthritis of the knee results from years of wear and tear. Cartilage provides a buffer in the joint between the bones to allow smooth, easy movement. Over time, this cartilage begins to break down and become brittle. Without enough cartilage to protect the bones from rubbing together and causing damage, this friction leads to swelling and painful inflammation. Ultimately, stiffness and soreness can limit mobility, and make moving the joint very painful.

Stem Cell Therapy cells are powerful healing agents that, when used in concentrated doses, can quickly reduce inflammation and scar tissue, and enhance the natural healing processes of the body. Regenerative Cell Therapy is a non-invasive, in-office procedure that safely and effectively alleviates osteoarthritis pain.

When the meniscus cartilage ruptures due to traumatic injuries or due to age-related wear and tear, it is referred to as a meniscus tear. A meniscus tear is usually very painful and limiting. The knee will not operate correctly with this type of injury. The meniscus is located at the knee joint. It is a rubbery piece of cartilage that acts as the bodys shock absorber and also acts as a pad to stabilize and protect the knee. Meniscus tears are of three degrees: severe, moderate and minor. A severe meniscus tear is when bits of ruptured meniscus enter the knee joint and affects the function of the knee causing a lot of pain. But for minor and moderate meniscus tears, the pain usually disappears after conventional treatment or a few weeks of rest. Those suffering from a meniscus tear are increasingly becoming aware of the implications of removing the meniscus though surgical operation. They also prefer not to risk the side effects that come with steroid injections. Wisconsin Stem Cell Therapy offers a non-invasive alternative to surgery and steroid injections for this problem. We also treat the underlying issues that cause the pain using either Wisconsin Stem Cell Therapys advanced form of Anmniotic Regenerative Cell Therapy. By using this regenerative approach, the medical collateral ligament can repair itself and regain its function of holding the knee bones in place, thus relieving pressure on other components such as the particular cartilage and meniscus.

Degeneration of the joints can occur in any of the joints in the body, especially those that experience lots of wear and tear. The knees are used in so many daily motions, feeling pain with each movement is debilitating. Joint degeneration generally develops over time, but can suddenly worsen and become more severe and disabling. Cartilage or other soft tissues within the knee joint can begin to dehydrate, deteriorate, or become damaged from some type of injury. These tissues provide a protective cushion between the bones for smooth movement. Once these start to wear down, or degenerate, friction within the joint can lead to inflammation, swelling, bone spurs, and other painful symptoms. Recent developments in Stem Cell Therapy make it possible to treat degenerative joint conditions naturally, without the need for medications, steroids, or surgery. Stem Cell Therapy uses these cells to target the damaged and deteriorating tissues. Concentrated amounts of these cells are injected into the affected area, and immediately reduce inflammation and reverse damage and deterioration of tissue.

The posterior cruciate ligament (PCL) and anterior cruciate ligament (ACL) are both major ligaments providing strength and stability within the knee joint. Ligaments are thick bands of tissue that connect bones. Injuries to these connective tissues are painful, debilitating, and have historically been a challenge to treat and heal. In the past, these kinds of injuries could cause what was considered permanent damage to the knee joints. Traditionally, the most common treatment for torn ligaments in the knee is arthroscopic surgery and reconstruction. Developments in regenerative medicine make effective, natural treatment of PCL and ACL injuries within reach. Procedures like Stem Cell Therapy offer non-surgical treatment options for those suffering from knee injuries and damage to soft tissues in the joints. Using these cells in concentrated amounts to target the injured area, the body is able to reduce inflammation and heal itself naturally.

Also known as runners knee, chondromalacia is inflammation of the underside of the kneecap, and deterioration of the cartilage that supports it. When this cartilage is damaged or wears down, it becomes difficult to bend and straighten out the leg. This condition is common among young athletes, but may also be present in older individuals with arthritis of the knee. Stem Cell Therapy and other regenerative medicine techniques offer natural treatment alternatives to pain medications, steroid injections, and surgery. Using these cells, our specialists are able to target specific areas of inflammation or injury and restore damaged tissues. These are cutting-edge techniques that have provided relief and healing to so many of our patients with knee pain.

Read more from the original source:
Knee Conditions Milwaukee, WI | Wisconsin Stem Cell Therapy

Stem Cell Therapy for General Hip Pain

Hip pain is a common problem that affects many people making it difficult to walk, stand and sit. Hip pain has many causes, making it essential to be evaluated properly to find the true cause. There are many conditions that can cause hip pain, including osteroarthritis, bursitis, tendonitis, and osteonecrosis.

Wisconsin Stem Cell Therapys doctors have extensive experience when it comes to hip pain treatment. We have pioneered the industrys latest proven alternatives to surgery and steroids. Our in-office, same-day procedures will alleviate your hip pain regardless of the cause. Our revolutionary platelet rich plasma (PRP) and regenerative cell procedures treat all the damage and underlying conditions that cause you pain. Our surgeons use stem cell therapy to rebuild and strengthen the damaged tissue of your hip, eliminating your pain and improving your quality of life.

Osteoarthritis of the hip results from years of wear and tear. Cartilage provides a buffer in the joint between the bones to allow smooth, easy movement. Over time, this cartilage begins to break down and become brittle. Without enough cartilage to protect the bones from rubbing together and causing damage, this friction leads to swelling and painful inflammation. Ultimately, stiffness and soreness can limit mobility, and make moving the joint very painful.

Traditionally, hip pain has been difficult to treat, with pain medications, steroid injections, or even surgery being the best possible treatment options. Fortunately, recent developments in technology and medicine make it possible to treat osteoarthritis pain naturally. Stem Cell Therapy cells are powerful healing agents that, when used in concentrated doses, can quickly reduce inflammation and scar tissue, and enhance the natural healing processes of the body. Regenerative Cell Therapy is a non-invasive, in-office procedure that safely and effectively alleviates osteoarthritis pain.

A labrum tear is caused in many different ways. Sports injuries are the main cause of labrum tears. The reason is that the outermost part of the labrum attaches directly to the tendon. So the athletes who use a lot of force and motion such as weightlifters, golfers and baseball pitchers are at high risk of this type of injury.

Traumatic injury is the most common cause of a tear. Traumatic injury may result from a situation such as falling in a manner that puts strain on the hip or a direct blow or sudden pull. Furthermore, a labrum tear can result from degradation of the cartilage from overuse, repetitive motion and a dislocated hip.

If you are suffering from labrum tear, you can visit us for a painless alternative to cortisone injections and/or surgery. After undergoing our procedure it will take you a very short time to recover. Wisconsin Stem Cell Therapys procedure for labrum tears includes stem cell therapy. This procedure reduces the risk associated with traditional surgery and treats the underlying damage causing the pain. These cells accelerate the healing process by making the conditions in the affected area more conducive to repair and stimulating the movement of regenerative cells towards the site of inflammation.

The hips are often the most used joint in the body, and over time take a lot of wear and tear. Hip degeneration is a condition that usually develops and worsens over a long period of time and with the aging process. Some may not notice any symptoms in the first stages, and then they may appear suddenly. When the cartilage protecting and surrounding the hip bones begins to wear down, those bones can begin to rub together. This friction between the bones eventually causes severe pain, inflammation, and swelling. It may cause stiffness, limit the joints range of motion, or even lead to the development of bone spurs.

Advanced developments in regenerative medicine now make it possible to effectively treat pain from hip degeneration without prescription medications or steroid injections. In many cases, it may even help some sufferers avoid high-risk surgeries. Procedures like Stem Cell Therapy take regenerative cells and use them to heal specific areas of damaged tissue. When inflammation and aging slows down the natural production of these cells, providing the body with them in concentrated levels quickly reduces pain, inflammation, and scar tissue. This process provides support for the immune system to help heal damage and degeneration within the hip joint.

Inside the larger joints of the body are small, fluid-filled sacs called bursae that provide cushioning between muscles, bones and tissues, allowing them to move smoothly without friction. Bursitis is a condition involving the inflammation of one or more of these bursae. It can occur within the hip joints, causing mild to severe pain and stiffness, while making movement uncomfortable.

Treatment for bursitis should first reduce the inflammation that is causing the pain and stiffness in the hip joint. Stem Cell Therapy is one of our advanced treatment options that takes concentrated amounts of healing cells, and uses them to treat the specific area of inflammation and damage. Stem Cell Therapy is a revolutionary solution to heal degeneration of soft joint tissues and a safe alternative to medications, steroid injections, and surgery. This is a non-surgical procedure that can be done in-office to quickly and naturally alleviate your hip pain.

See the article here:
Stem Cells for Hip Brookfield, WI | Wisconsin Stem Cell ...

On a Sunday morning national news broadcast, Mike West, an official at Geron Corporation, effusively affirmed that ethical iPS cells are the future of stem cell research. West stated several times that iPS cells are without controversy and the path which unites scientists and the country to pursue promising stem cell research to treat debilitating illnesses.

West described for a national audience how four molecules are used to take ordinary cells and turn them back to their embryonic state, resulting in iPS cells. No one has to die in this reprogramming process.

Geron Corporation, located in California, has been a major player in embryonic stem cell research. Earlier this year, Geron was given clearance by the FDA to conduct the first human embryonic stem cell trials. Thats why it was so interesting to hear West speak approvingly of ethical iPS cell research as the future.

Wests statements also corroborate what Wisconsin Right to Life and others stated last week following Obamas reversal of the Bush policy prohibiting federal funding to kill more human embryos: Obama is turning back the clock and using ideology to trump science.

Barbara Lyons

Read this article:
Geron Official Affirms iPS Cells Are the Future of Stem ...